Clinical Trials Logo

Cognition Disorders clinical trials

View clinical trials related to Cognition Disorders.

Filter by:

NCT ID: NCT01132261 Completed - Cognitive Decline Clinical Trials

Trial of a Brain Preservation Diet in Preventing Cognitive Decline in Old Age Hostel Residents

Start date: February 2006
Phase: N/A
Study type: Interventional

Dementia is a major cause of disabilities in older people. If the onset of dementia can be delayed by preventive measures, the burden of the disease to the society can be greatly reduced. It is now recognised that dietary factors are related to the incidence of dementia. High intake of vegetables, fruit and fish are protective while high intake of saturated fat and salt (via its effect on blood pressure) are detrimental to risk of dementia. The investigators therefore propose to perform a randomized controlled trial of dietetic interventions in old age hostels in Hong Kong. Twelve old age hostels under the Tung Wah Group will be randomly assigned to intervention or control groups. The intervention group will receive dietetic interventions by 2 weekly small group discussion with the residents, modification of menu and publicity. The daily diet to be implemented consists of the following principles: 1. fresh fruit 2 portions, 2. vegetables 4 portions, 3. fish, 4. white meat, 5. sodium intake < 100 mmol/L, 6. six glasses of water. In the control group. The dietician will give two health talks and advice on menu only. The primary outcome is the incidence of questionable dementia in those who are normal at baseline and the incidence of dementia in those who have questionable dementia at baseline. The categorisation will be performed by trained research assistant after administering a structured questionnaire. Change in mini-mental examination score and SF36 quality of life scores are secondary outcomes. Food records over three days for each subject are recorded every three months, to ensure that the brain preservation diet has been adhered to. Half of the subjects will be randomly assigned to have blood and urine tests at baseline and at one year, in order to examine the health effects of dieting.

NCT ID: NCT01121497 Not yet recruiting - Clinical trials for Cognitive Dysfunction

The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy

Start date: July 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the administration of physostigmine in combination with sedation for colonoscopy can minimize the cognitive decline at the time of hospital discharge

NCT ID: NCT01109836 Completed - Dementia Clinical Trials

Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke

ASPIS
Start date: June 2010
Phase: Phase 4
Study type: Interventional

Aim of this randomized controlled study is to test if intensive polyintervention therapy including life style modifications targeting at reduction of modifiable risk factors of stroke can reduce the risk of post-stroke cognitive decline compared to a group of patients receiving standard care.

NCT ID: NCT01106768 Recruiting - Clinical trials for Attention Deficit Disorder With Hyperactivity

Evaluation of Oral Needs of Children With Disorder Attention Deficit/Hyperactivity Disorder

Start date: May 2009
Phase: N/A
Study type: Observational

There is little accurate data in the literature at present on oral problems of hyperactive children, especially regarding care needs that would justify an assumption oral specific. The purpose of this study is therefore to have accurate data regarding the risk of caries, other oral diseases like periodontal disease, trauma, and assess the needs dental care and problems in cooperation for dental care in a population of children and adolescents with hyperactivity disorder with attention deficit. Finally, it has recently been described as the sleep disordered breathing was not uncommon in disorder attention deficit/hyperactivity disorder, whether snoring and/or apnea. But it is now accepted that some features of facial morphology favoring pharyngeal congestion occur in individuals with obstructive sleep apnea (hyperdivergent typology with increased anterior facial height and decreased posterior facial height, becoming the facial retrognathia, pharyngeal congestion, elongation and thickening of the soft palate, low position of the hyoid bone). A cephalometric analysis of craniofacial architecture and relationships with the soft tissue surrounding skeletal structures will detect if any of these specific characteristics that could promote sleep disordered breathing are found in disorder attention deficit/hyperactivity disorder prevalence with a particular.

NCT ID: NCT01103752 Completed - Clinical trials for Postoperative Cognitive Dysfunction

Postoperative Cognitive Dysfunction After Total Knee or Hip Replacement Surgery in Fast-track Set-up

Start date: October 2009
Phase: N/A
Study type: Observational

The aim of this study is to quantify the incidence of postoperative cognitive dysfunction in the elderly patient (>60y) after total hip or knee replacement surgery. The hypothesis is that the fast-track methodology with a mean hospital stay less than 3 days will help to minimize this reduction in memory and concentration.

NCT ID: NCT01099332 Active, not recruiting - Clinical trials for Mild Cognitive Impairment

Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease

Start date: November 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This trial aims to test the hypothesis that 1) a single dose of zinc cysteine in a proprietary gastro-retentive form will produce sustained blood levels of zinc giving a larger bioavailable amount of zinc than an FDA approved preparation of inorganic zinc acetate; and 2) that the zinc cysteine gastro-retentive, sustained-release preparation will be better tolerated with significantly less gastrointestinal side effects than the zinc acetate capsules. The trial also tests the hypothesis that, after 6 months of once daily administration, the zinc cysteine subjects will show reduced serum non-ceruloplasmin copper. Additionally, subjects will perform tests of mental function,including the dementia rating scale, the Mini Mental Status Examination and the ADAS-cognitive performance test aimed at Alzheimer's status assessment. Tests will be administered at baseline, 3 and 6 months, and the performance results compared. Care-giver assessments will also be noted.

NCT ID: NCT01095562 Completed - Clinical trials for Cognitive Deficits in Schizophrenia

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Start date: March 2010
Phase: Phase 2
Study type: Interventional

This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.

NCT ID: NCT01094145 Completed - Alzheimer Disease Clinical Trials

Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease

MeynD-DBS
Start date: January 2010
Phase: N/A
Study type: Interventional

In the study at hand, six patients with light to moderate Alzheimer's disease will be enrolled and implanted with bilateral electrodes in the nucleus basalis Meynert.

NCT ID: NCT01088100 Completed - Clinical trials for Cognitive Impairment

Study of the Correlation Between Specific Genes and Cognitive Dysfunction After Surgery

Start date: August 2010
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether a certain clock-gene (HPER3) with the 5/5 genotype carries a higher risk of post-operative cognitive dysfunction.

NCT ID: NCT01078636 Completed - Clinical trials for Mild Cognitive Impairment

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

ADNI-GO
Start date: April 2010
Phase: N/A
Study type: Observational

The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI-GO seeks to define and characterize the mildest symptomatic phase of AD, referred to in this study as early amnestic MCI (EMCI). This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.